BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1073 related articles for article (PubMed ID: 12771727)

  • 1. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
    Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
    J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma.
    Veeramachaneni R; Nordberg ML; Shi R; Herrera GA; Turbat-Herrera EA
    Diagn Cytopathol; 2003 Jun; 28(6):301-7. PubMed ID: 12768634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice.
    Laudadio J; Keane TE; Reeves HM; Savage SJ; Hoda RS; Lage JM; Wolff DJ
    BJU Int; 2005 Dec; 96(9):1280-5. PubMed ID: 16287445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
    Bergman J; Reznichek RC; Rajfer J
    BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma.
    Halling KC; King W; Sokolova IA; Meyer RG; Burkhardt HM; Halling AC; Cheville JC; Sebo TJ; Ramakumar S; Stewart CS; Pankratz S; O'Kane DJ; Seelig SA; Lieber MM; Jenkins RB
    J Urol; 2000 Nov; 164(5):1768-75. PubMed ID: 11025767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.
    Moonen PM; Merkx GF; Peelen P; Karthaus HF; Smeets DF; Witjes JA
    Eur Urol; 2007 May; 51(5):1275-80; discussion 1280. PubMed ID: 17084511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor.
    Casella R; Huber P; Blöchlinger A; Stoffel F; Dalquen P; Gasser TC; Lehmann K
    J Urol; 2000 Dec; 164(6):1926-8. PubMed ID: 11061883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings.
    Bubendorf L; Grilli B; Sauter G; Mihatsch MJ; Gasser TC; Dalquen P
    Am J Clin Pathol; 2001 Jul; 116(1):79-86. PubMed ID: 11447756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.
    Lotan Y; Bensalah K; Ruddell T; Shariat SF; Sagalowsky AI; Ashfaq R
    J Urol; 2008 Jun; 179(6):2164-9. PubMed ID: 18423745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
    Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
    Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings.
    Yoder BJ; Skacel M; Hedgepeth R; Babineau D; Ulchaker JC; Liou LS; Brainard JA; Biscotti CV; Jones JS; Tubbs RR
    Am J Clin Pathol; 2007 Feb; 127(2):295-301. PubMed ID: 17210520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance.
    Johannes JR; Nelson E; Bibbo M; Bagley DH
    J Urol; 2010 Sep; 184(3):879-82. PubMed ID: 20643443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria.
    Sarosdy MF; Kahn PR; Ziffer MD; Love WR; Barkin J; Abara EO; Jansz K; Bridge JA; Johansson SL; Persons DL; Gibson JS
    J Urol; 2006 Jul; 176(1):44-7. PubMed ID: 16753364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
    Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
    Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of nondiagnostic molecular changes in urine detected by UroVysion fluorescence in situ hybridization during surveillance for bladder cancer.
    Nguyen CT; Litt DB; Dolar SE; Ulchaker JC; Jones JS; Brainard JA
    Urology; 2009 Feb; 73(2):347-50. PubMed ID: 19022486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples.
    Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Zilberstien Y; Friberger A; Kidron D; Kaplan E; Lew S; Leibovitch I
    Urology; 2005 Dec; 66(6):1354-9. PubMed ID: 16360483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence in situ hybridization assay detects upper urinary tract transitional cell carcinoma in patients with asymptomatic hematuria and negative urine cytology.
    Huang WT; Li LY; Pang J; Ruan XX; Sun QP; Yang WJ; Gao X
    Neoplasma; 2012; 59(4):355-60. PubMed ID: 22489689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.
    Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R
    Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
    Halling KC; King W; Sokolova IA; Karnes RJ; Meyer RG; Powell EL; Sebo TJ; Cheville JC; Clayton AC; Krajnik KL; Ebert TA; Nelson RE; Burkhardt HM; Ramakumar S; Stewart CS; Pankratz VS; Lieber MM; Blute ML; Zincke H; Seelig SA; Jenkins RB; O'Kane DJ
    J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.